These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9568837)

  • 1. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency.
    Macdougall IC
    Nephrol Dial Transplant; 1998 Apr; 13(4):847-9. PubMed ID: 9568837
    [No Abstract]   [Full Text] [Related]  

  • 2. What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Measurement of hypochromic red blood cells is not the first line procedure to identify the patient with iron deficiency.
    Hörl WH
    Nephrol Dial Transplant; 1998 Apr; 13(4):850-1. PubMed ID: 9568838
    [No Abstract]   [Full Text] [Related]  

  • 3. Zinc protoporphyrin and percentage of hypochromic erythrocytes as markers of functional iron deficiency during therapy with erythropoietin in patients with advanced acquired immunodeficiency syndrome.
    Matzkies FK; Cullen P; Schaefer L; Hartmann M; Hohage H; Schaefer RM
    South Med J; 1999 Dec; 92(12):1157-61. PubMed ID: 10624905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
    Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
    Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy.
    Schaefer RM; Schaefer L
    J Perinat Med; 1995; 23(1-2):83-8. PubMed ID: 7658326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and therapy of renal anemia].
    Szegedi J
    Orv Hetil; 2008 Feb; 149(6):251-5. PubMed ID: 18238714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Blood doping' with recombinant erythropoietin (rhEPO) and assessment of functional iron deficiency in healthy volunteers.
    Breymann C; Rohling R; Krafft A; Huch A; Huch R
    Br J Haematol; 2000 Mar; 108(4):883-4. PubMed ID: 10792301
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
    Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
    Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin resistance].
    Branger B
    Nephrologie; 2002; 23(1):3-5. PubMed ID: 11887576
    [No Abstract]   [Full Text] [Related]  

  • 11. [Individual differences in the efficacy of Recormon in patients with terminal kidney failure. The role of iron deficiency].
    Nikolaev AIu; Klepikov PV; Lashutin SV; Kondakhchan MA; Rogov VA; Trofimova EI
    Ter Arkh; 1993; 65(6):45-8. PubMed ID: 8378849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reappearance of pica symptoms during erythropoietin treatment].
    Duclos J
    Rev Med Chil; 1992 Mar; 120(3):296-9. PubMed ID: 1342483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 14. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin.
    Fialon P; Leaute AG; Sassier P; Vallot C; Wone C
    Pathol Biol (Paris); 1993 Dec; 41(10):931-5. PubMed ID: 8159473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
    Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin.
    Macdougall IC
    Nephrol Dial Transplant; 1998; 13 Suppl 2():23-7. PubMed ID: 9566487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors determining the percentage of hypochromic red blood cells in hemodialysis patients.
    Bovy C; Tsobo C; Crapanzano L; Rorive G; Beguin Y; Albert A; Paulus JM
    Kidney Int; 1999 Sep; 56(3):1113-9. PubMed ID: 10469381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of functional iron deficiency status in haemodialysis patients in central South Africa.
    Haupt L; Weyers R
    Int J Lab Hematol; 2016 Aug; 38(4):352-9. PubMed ID: 27136325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.